Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II, Multicentre Clinical Trial to Evaluate the Activity of Encorafenib and Binimetinib Administered Before Local Treatment in Patients With BRAF Mutant Melanoma Metastatic to the Brain

NCT03898908 is registered in ClinicalTrials.gov with Grupo Español Multidisciplinar de Melanoma as lead sponsor.

NCT NCT03898908
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03898908 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II, Multicentre Clinical Trial to Evaluate the Activity of Encorafenib and Binimetinib Administered Before Local Treatment in Patients With BRAF Mutant Melanoma Metastatic to the Brain
Lead sponsor
Grupo Español Multidisciplinar de Melanoma
Phase
Phase 2
Overall status
Completed
Start date
July 18, 2019
Completion date
July 31, 2023
Enrollment
48 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

brain metastases, metastatic melanoma